GeneDx is trading 4.3% lower at $72.52 as shares extend a multi-day slide amid scrutiny following a short-seller report. - Shares fell 11.80% on September 29; the report’s allegations are not independently established here. - No new company announcement explaining the September 30 move surfaced in search results; supplied indices were mixed, with no clear broad-market explanation. - Coverage is limited, and an earlier company-news summary identified no specific September 29 catalyst; confidence is low.